67 MSEK in new funding
We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.
Per von Mentzer, CEO, comments:
"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."
Göran Lerenius, Chairman of the board, comments:
"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."
More information:
67 MSEK in new funding
We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.
Per von Mentzer, CEO, comments:
"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."
Göran Lerenius, Chairman of the board, comments:
"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."
More information:
Latest news
View all
CTA submission for PN6047
PharmNovo AB is pleased to announce that the clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been submitted in Spain. The full title of the application is: “Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia.” Based on a strategic company decision, PharmNovo has submitted the CTA, in the first instance, to the Spanish Health Authorities only. Submission to the Czech Republic and Poland, the two other countries in which the trial will be conducted, is planned to take place following approval in Spain, which is expected by October 2025. Subject to additional investment, patient enrolment is expected to start by Quarter 1 2026.
Read more
PharmNovo at the LSX World Congress in London
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Congress in April 2025 in London. PharmNovo is redefining pain management with PN6047, a first-in-class Delta Opioid Receptor Agonist (DORA), safer, non-addictive solution for neuropathic pain. Unlike traditional opioids, PN6047 eliminates concerns of side effects, abuse potential, and tolerance. With a proven safety profile from Phase I trials and a market projected to exceed EUR 13 billion by 2033, PN6047 is set to be a game-changer.
Read more
Positive FDA feedback for PN6047
PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.
Read more
Pioneering approach to treat neuropathic pain
PharmNovo has recently published an article in MedNous, highlighting the pioneering approach to tackling neuropathic pain without the risks traditionally associated with opioids. The lead candidate, PN6047, targets the delta-opioid receptor – offering pain relief without addiction or sedation. Arrangements for a Phase II trial have now been completed, marking a crucial step toward a safer alternative for millions suffering from chronic pain. With the opioid crisis still a major concern, innovative, non-addictive treatments like PN6047 are more urgent than ever.
Read more